Press Release FeedGet the RSS feed
Menu

Business Wire

NUCLIDIUM and NorthStar Enter Long-term Strategic Partnership to Advance NUCLIDIUM’s Copper-67 Radiotheranostic Oncology Pipeline

Business Wire

  • Collaboration spans Copper-67 supply and radiopharmaceutical manufacturing from clinical development through commercialization.

  • Partnership leverages NorthStar's vertically integrated campus, combining proprietary Copper-67 production technology, cGMP manufacturing, and commercial-scale infrastructure.

BASEL, Switzerland & MUNICH & BELOIT, Wis., October 19, 2026--NUCLIDIUM AG, a clinical-stage radiopharmaceutical company, and NorthStar Medical Technologies, LLC (NorthStar), a global radiopharmaceutical supply-chain partner, today announced a long-term strategic partnership through which NorthStar will produce Copper-67 (Cu-67) and provide comprehensive radiopharmaceutical manufacturing services to support NUCLIDIUM's therapeutic programs from clinical development through commercialization. Copper-67 is the therapeutic isotope component of NUCLIDIUM's radiotheranostic programs to treat cancers with high unmet medical need.

The partnership underscores NUCLIDIUM and NorthStar's mutual commitment to expanding global patient access to precision radiopharmaceutical therapies. NUCLIDIUM's pipeline includes lead programs NU101 addressing metastatic castration resistant prostate cancer (mCRPC) and NU201 for metastatic breast cancer (mBC) as well as earlier stage programs in other solid tumor indications with a focus on women's oncology.

The work will be led through NorthStar's vertically integrated U.S.-based radiopharmaceutical campus, where the company has pioneered advanced isotope production technologies, made significant investments in cGMP manufacturing, and maintains commercial-scale infrastructure to support growing global demand for targeted radiopharmaceutical therapies. NorthStar's comprehensive approach enables a seamless transition from clinical development to commercialization, while reducing supply-chain complexity and accelerating program execution.

"Our collaboration with NorthStar strengthens our copper isotope supply chain at a critical moment, ensuring we are well prepared to execute on our near-term clinical development objectives and meet the long-term demand for our radiotheranostics," said Leila Jaafar, PhD, CEO and Co-Founder of NUCLIDIUM. "NUCLIDIUM remains on track to initiate multiple therapeutic studies utilizing Copper-67 for mCRPC and mBC in the coming months, while expanding our radiotheranostic portfolio into the clinic, including specifically women´s oncology indications."

"As demand for copper-based radiotheranostics continues to grow, reliable isotope supply and scalable manufacturing infrastructure will be essential for successful commercialization," said Dr. Frank Scholz, President & CEO of NorthStar. "NorthStar's integrated platform is designed to provide both, allowing NUCLIDIUM to advance its programs efficiently from clinical development through future commercial launch."

  1. HealthcarePureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026Oral presentation to highlight encouraging clinical activity and favorable safety of LYT-200 in heavily pretreated patients with R/R HR-MDS and AML Results reinforce the potential of LYT-200 as a first-in-class, mutation-agnostic treatment for a broad R/R HR-MDS population, where treatment options remain extremely limited
  2. SaaSeLstar Dynamics Launches the World’s First Commercial ELM Smart Glass Solution for Architectural Glazing, Harking in a New Era for Controlling Sunlight Without Compromising DesignExplore eLstar's Latest Smart Glass Innovations at Glasstec in Düsseldorf in Hall 10, Stand A12 DUSSELDORF, Germany, October 19, 2026--Today at Glasstec 2026, eLstar Dynamics announced the commercial availability of its first Electrophoretic Light Modulation (ELM) Platform . Purpose-built specifically
  3. Azelis: Transparency notifications from UBS Group AGCompanies: UBSANTWERP, Belgium, October 19, 2026--REGULATED INFORMATION In accordance with Article 14 of the Belgian Transparency law of 2 May 2007, Azelis Group NV (Brussels:AZE) announces that on 13 October 2026, it has received two transparency notifications from UBS Group AG. 1. Summary of the notifications UBS
  4. FinancePoxel Reports Revenue for the Third Quarter of 2026Consolidated net sales of TWYMEEG ® in Japan for the third quarter of 2026 reached JPY 2.9 billion (€16.3 million 1 ), up 29% compared to the third quarter of 2025. Consolidated net sales of TWYMEEG ® in Japan for the first nine months of 2026 reached JPY 8.1 billion (€44.5 million 1 ), up 32% compared to the first nine m
  5. FinanceBW LPG LimitedBW LPG Limited – Update on BW LPG’s Product Services Q3 2026 Segment PerformanceSINGAPORE, October 19, 2026--BW LPG Limited ("BW LPG" or the "Company", OSE ticker code: "BWLPG.OL", NYSE ticker code: "BWLP") today provides an update on its Product Services' ("BW Product Services") Q3 2026 segment performance. Q3 2026 highlights: Gross trading result: US$164 million This includes: R
  6. HealthcareGenentechGenentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage PortfolioPhase III Krascendo 1 results demonstrated divarasib's superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung cancer Patient-reported outcomes from Phase III lidERA study showed improved efficacy of giredestrant over standard endocr